Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma

Objective: Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of R-DA-EDOCH immunochemotherapy in treating aggressive B-cell lymphomas, we designed...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi Wang, Yuting Yan, Dandan Shan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Wenjie Xiong, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Dehui Zou, Shuhua Yi
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-02-01
Series:Cancer Biology & Medicine
Subjects:
mantle cell lymphoma
immunochemotherapy
high-risk factors
minimal residual disease
adverse events
Online Access:https://www.cancerbiomed.org/content/22/2/177
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.cancerbiomed.org/content/22/2/177

Similar Items